We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock

Delisted

KDNY was delisted on the 10th of August, 2023.

77 hedge funds and large institutions have $366M invested in Chinook Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $328M → $366M (+$38.4M)

0% more funds holding

Funds holding: 7777 (0)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

38% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 26

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1M

Holders
77
Holders Change
Holders Change %
0%
% of All Funds
1.35%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
8
Increased
16
Reduced
26
Closed
8
Calls
Puts
$1M
Net Calls
-$1M
Net Calls Change
-$402K

KDNY Hedge Fund Activity: Q1 2021 in Review

77 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2021, worth a combined $366M — up 12% from $328M a quarter earlier.

Fund positioning in KDNY was balanced in Q1 2021: 8 funds opened new positions, 8 closed out, 16 added to existing stakes and 26 trimmed.

The largest buyer was Millennium Management, adding an estimated $5.04M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $4.33M sold.

  • 77 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $366M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2021, up 12% quarter-over-quarter.
  • 8 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of 0 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2021 was Millennium Management, an estimated $5.04M added.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2021 was Monashee Investment Management, an estimated $4.33M sold.

Based on aggregated 13F filings for Q1 2021.